BC-1258;BC-1258, 10 mM in DMSO;N1,N2-Bis(4-(thiazol-2-yl)benzyl)ethane-1,2-diamine;N,N′-Bis-(4-thiazol-2-yl-benzyl)-ethane-1,2-diamine;1,2-Ethanediamine, N1,N2-bis[[4-(2-thiazolyl)phenyl]methyl]-;N,N'-bis[[4-(1,3-thiazol-2-yl)phenyl]methyl]ethane-1,2-diamine;LRR,F-box,inhibit,repeat,BC-?1258,BC ?1258,FBXL2,Apoptosis,tumor,Inhibitor,BC?1258;LRR|||F-box|||BC1258|||inhibit|||repeat|||BC-1258|||BC-1258|||BC-?1258|||BC ?1258|||FBXL2|||Apoptosis|||BC-1258|||tumor|||Inhibitor|||BC?1258|||BC 1258
BC-1258 (N,N′-Bis-(4-thiazol-2-yl-benzyl)-ethane-1,2-diamine) is a potent activator of unique E3 ligase F-box/LRR-repeat protein 2 (FBXL2) that increases levels of FBXLs protein, thus promoting Aurora B degradation. BC-1258 induces mitotic arrest and apoptosis of tumorigenic cells. Also BC-1258 inhibits tumor formation in athymic nude mice.
